The Brazilian Interdisciplinary AIDS Association (ABIA) is a non-profit non-governmental organization that was founded in 1987 and acts in the mobilization of civil society against HIV, for access to treatment and the defence of human rights of people living with HIV (PLHIV).
ABIA plays a unique role in Brazil, working in partnership with the government on intellectual property (IP). It has conducted extensive research around laws and policies affecting antiretrovirals (ARVs), direct-acting antivirals (DAAs), and patents, and is a well-respected technical advisor.
ABIA has filed many critical and successful patent oppositions, including on dolutegravir, molnupiravir, and cabotegravir.